Sexual health

How Well PrEP Works Against HIV

Save

The headline figure for PrEP — about 99% — is real, but it is easy to misread. It is a risk reduction, not a promise, and it assumes the medicine is actually in your system when an exposure happens. This page unpacks what the number means, why adherence is the whole game, what PrEP does not cover, and how it compares with an undetectable partner's near-zero risk.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

How well does PrEP actually work?

Taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99% 1. For people who inject drugs, it lowers the risk by at least 74% 1. Those are among the most effective prevention tools in medicine — close to, but not exactly, complete protection. The wording matters here: this is a large reduction in risk, not a guarantee of zero, and every part of the figure rests on the drug being present and taken consistently. PrEP cuts the risk of sexually acquired HIV by roughly 99% when taken as prescribed 1. Read that as an extraordinary lowering of risk, not as immunity.

Why adherence is the whole story

The distance between PrEP's best-case number and a person's real-world protection is almost entirely about consistency. PrEP works by keeping enough drug in the body that HIV cannot establish itself; miss doses and that concentration falls, and the protection falls with it. This is why prescribing is wrapped in regular monitoring and support rather than a one-time handoff — the 2021 U.S. clinical practice guideline treats PrEP as an ongoing relationship, not a single prescription 2. The 99% figure is not really a property of the pill; it is a property of taking the pill consistently. For most people the practical question is not whether PrEP is effective, but whether the chosen routine — one of several prep options, whether daily, on-demand, or the shot — is one they can actually keep up. Studies that followed people taking PrEP found the same pattern over and over: where drug levels stayed high, new infections were extraordinarily rare, and nearly every breakthrough traced back to doses that were not being taken. The medicine did its part; the misses were where risk crept in.

Where the 99% comes from — and what it doesn't promise

The effectiveness figures come from clinical trials and large real-world studies of people taking PrEP, and they describe populations, not guarantees for any single act. On an individual level, protection depends on whether enough drug has built up in the tissue that gets exposed — which varies with how long someone has taken it and how consistently. That is why careful sources describe PrEP as highly effective and reducing risk by about 99%, and never as making someone immune 1. Rare breakthrough infections have happened, usually tied to missed doses and occasionally to a resistant virus. None of that is a reason to distrust PrEP. It is a reason to read the number as what it is: an exceptional reduction in risk, not a force field. It also helps to separate two words that get blurred together: efficacy, how well a drug performs under ideal, closely monitored trial conditions, and effectiveness, how well it performs in ordinary life. PrEP's numbers are strong on both counts, but the everyday figure always leans on the human part — remembering, refilling, and staying in care.

What PrEP does not protect against

PrEP is aimed at HIV and nothing else. It offers no protection against gonorrhea, chlamydia, syphilis, herpes, HPV, or any other STI 1. That is not a flaw — it is the boundary of the tool, and it is why the same clinicians who prescribe PrEP also recommend regular STI screening and, for many people, barrier methods. The CDC's screening intervals are built around who you are and how you have sex, independent of PrEP 3, and consistent condom use adds the fluid-borne-STI protection PrEP was never designed to give 4. An internal condom is one more option in that layer. PrEP plus screening plus barriers is not belt-and-suspenders excess; each covers a genuinely different risk.

PrEP versus an undetectable partner: two routes to near-zero

There is a second path to almost no risk that does not involve PrEP at all. A partner living with HIV who takes treatment and maintains an undetectable viral load has effectively no risk of transmitting the virus sexually — the principle known as ==term: Undetectable = Untransmittable (U=U)== 5. For a couple where one partner has HIV and one does not, that reshapes the picture: the HIV-negative partner may take PrEP, the treated partner's undetectable status may carry the protection, or both can hold at once. Between U=U and PrEP, a mixed-status couple has more than one well-supported way to reach near-zero risk. Which combination fits is a conversation with a clinician, not a fixed rule.

When PrEP is most — and least — protective

PrEP is not protective the moment you swallow the first pill. It needs time to reach full concentration in the relevant tissue, so there is a ramp-up window before it is working at the level the headline number describes — the reason people ask how long until PrEP is effective. It is also most reliable when HIV status is confirmed negative before starting, which is timing-sensitive: a nucleic-acid test detects HIV roughly 10 to 33 days after exposure, and antibody tests take longer to turn positive 6. Protection is highest during steady use and lowest during gaps — a run of missed doses, a lapse in refills, or the period around stopping prep. This is where a reliable prep lab schedule and easy refills matter, and telehealth prep exists largely to keep that routine unbroken. The pattern holds throughout: PrEP rewards continuity.

Common questions

No, and no honest source claims it is. Taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99% — an enormous reduction, but a reduction, not a guarantee. The gap between 99% and 100% is filled mostly by missed doses and, rarely, a resistant virus. Read the figure as extraordinary protection that still rewards consistency, not as immunity.

One missed dose is not the same as stopping, but PrEP works by keeping a steady drug level, and repeated misses let that level fall. Daily PrEP has some forgiveness built in, but the protection described by the 99% figure assumes consistent use. If doses are slipping often, that is worth a conversation about a routine — including the every-two-months shot — that is easier to keep.

PrEP reduces the risk of getting HIV through injection drug use by at least 74% when taken as prescribed. That is a meaningful reduction, though lower than the roughly 99% figure for sexual exposure. As with sexual risk, the protection depends on consistent use, and PrEP works best alongside sterile injection equipment and other harm-reduction tools, not in place of them.

Both oral and injectable PrEP are highly effective when used as prescribed. The injectable's advantage for many people is not a higher ceiling but a lower chance of missed doses — you cannot forget a daily pill you are not taking. The most effective option, in real life, tends to be the one a person can keep up with most reliably.

No. PrEP targets HIV alone and offers no protection against gonorrhea, chlamydia, syphilis, herpes, or HPV. That is why routine STI screening and, for many people, condoms remain part of the picture even on PrEP. The tools are complementary: PrEP handles HIV, while screening and barriers cover the infections it does not touch.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Signs to get checked, even on PrEP

  • —Flu-like illness — fever, sore throat, rash, muscle aches, swollen lymph nodes — a few weeks after a possible exposure, which can be a sign of acute HIV even in someone taking PrEP
  • —A run of missed PrEP doses around a higher-risk exposure
  • —New STI symptoms — unusual discharge, genital sores, or burning with urination — since PrEP does not protect against other infections

A possible HIV exposure during a gap in PrEP is time-sensitive — an emergency room or urgent care can assess whether PEP is needed within 72 hours.

This article explains how well PrEP works and what shapes that protection; it is general education, not medical advice or a promise about any individual's risk. Whether PrEP is right for you, which option fits, and how to combine it with testing and other prevention are decisions for a qualified clinician.

References

  1. 1.Centers for Disease Control and Prevention (2024). Clinical Guidance for PrEP. CDC HIV Nexus. linkThat PrEP taken as prescribed reduces the risk of getting HIV from sex by about 99% and from injection drug use by at least 74%, that oral and injectable options exist, and that PrEP does not protect against other STIs.
  2. 2.Centers for Disease Control and Prevention / US Public Health Service (2021). Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2021 Update: A Clinical Practice Guideline. CDC (stacks.cdc.gov). linkThat the 2021 U.S. clinical practice guideline frames PrEP as an ongoing prescription with regular clinical monitoring, and recommends informing sexually active adolescents and adults about PrEP.
  3. 3.Centers for Disease Control and Prevention (2021). STI Screening Recommendations. CDC STI Treatment Guidelines, 2021. linkCDC's population-specific STI screening intervals, which apply based on who a person is and how they have sex, independent of PrEP status.
  4. 4.Centers for Disease Control and Prevention (2024). Condom Use: An Overview. CDC (cdc.gov/condom-use). linkThat consistent, correct condom use is highly effective against HIV and STIs spread by genital fluids, adding protection PrEP does not provide against other STIs.
  5. 5.Centers for Disease Control and Prevention (2024). Undetectable = Untransmittable. CDC Global HIV and TB. linkThat a person with HIV who takes antiretroviral therapy and maintains an undetectable viral load has effectively no risk of sexually transmitting HIV (U=U), a route to near-zero risk alongside PrEP.
  6. 6.Centers for Disease Control and Prevention (2024). Clinical Testing Guidance for HIV. CDC HIV Nexus. linkHIV test window periods by test type (NAT ~10-33 days after exposure; antibody tests longer), used to explain why confirming HIV-negative status before starting PrEP is timing-sensitive.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library